« Return to News | Drug Sponsors | CROs/Service Providers

Recipharm, Astimex form development and manufacturing collaboration

Friday, October 12, 2012 11:58 AM

Recipharm, a Swedish contract development and manufacturing organization, and Astimex Pharma, a Swedish pharmaceutical company, have formed a collaboration agreement for the development and manufacture of a pharmaceutical product.

The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna, close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.

Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects. 

“I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma has chosen to utilize the expertise and flexible development capabilities that our staff and facilities are able to provide,” said Maria Lundberg, general manager, Recipharm Pharmaceutical Development.

“It is Recipharm’s recognized partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility, that attracted us in the first place,” said Åsa Lintzen, general manager, Astimex Pharma. “Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with Recipharm on other projects.”     

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.